{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 42,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/12",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.45,
        "y": 0.2
      },
      "kind": "chart",
      "text": "59.5% 60.5%",
      "attrs": {},
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9977560b-dd1c-4322-9165-e431efa4e7da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.4,
        "x": 0.54,
        "y": 0.67
      },
      "kind": "diagram",
      "text": "Anti-VEGF Injections Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec",
      "attrs": {},
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38111a20-e83c-4fec-9610-2a5e83c1f53d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.4,
        "x": 0.54,
        "y": 0.34
      },
      "kind": "diagram",
      "text": "Wait and Monitor for Progression Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec",
      "attrs": {},
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9c21dd9-b47b-41e7-ad46-b94992f8bdc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.42,
        "x": 0.01,
        "y": 0.6
      },
      "kind": "image",
      "text": "PDR 60, 61 Mild PDR 65 Moderate PDR 71-75 High-risk PDR 81-85 Advanced PDR 10",
      "attrs": {},
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a3ccc4a-c3cb-472d-9d1c-b9a6a75d82c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.42,
        "x": 0.01,
        "y": 0.32
      },
      "kind": "image",
      "text": "Mild to Moderate NPDR 10, 12 DR Absent 14, 15, 20 DR Questionable 35 Mild NPDR 43 Moderate NPDR 47 Moderately Severe NPDR 53 Severe NPDR",
      "attrs": {},
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f521a069-5ce4-417e-8a0f-ff8596faab0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.09,
        "x": 0.05,
        "y": 0.94
      },
      "kind": "image",
      "text": "Ocuphire PHARMA",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1050fc5c-2527-411e-845a-40ccddfce355",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "list",
      "text": "NPDR patients are monitored for progression requiring visits to the office every 4-6 months",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76472012-24e7-492d-8d03-230a8a4bd405",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "2021 ASRS PAT Survey Closely monitor retinopathy and encourage systemic glycemic control",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9886a528-a176-4e74-9bd9-a5fe329186ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.05,
        "y": 0.81
      },
      "kind": "list",
      "text": "Gold standard Eylea® and Lucentis® injections are effective treatments in the first year for PDR",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa5cc989-e04d-4416-ae4a-ed18e6982956",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.02,
        "x": 0.95,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "12",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59013368-be3f-4a14-801d-9c6c45f034df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.85,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "Currently, There Are No Non-Invasive Treatments Approved for Early Intervention or Slowing the Progression",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d362ac5-8fd1-4e06-bff5-f53338221a32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.59,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Current Standard of Care Based on Severity",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ecbc902-556a-4aef-8d4c-0ed8522ef22e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "658ab0ae-6284-4b3b-b67a-e6c8bfbdd666",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 11-16 present APX3330 as a solution for Diabetic Retinopathy",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}